What Rick Perry Told Joe Rogan About Ibogaine, And the Research That Says He's Right

Six months after a single dose of ibogaine, Rick Perry's neurologist showed him an MRI and told him the brain atrophy from a lifetime of concussions had disappeared. The scan, Perry told Joe Rogan, looked like the brain of a healthy forty-year-old. Perry is seventy-six.

That is the image the former Texas governor and 2016 presidential candidate opened with on The Joe Rogan Experience #2477, his second appearance alongside Americans for Ibogaine founder W. Bryan Hubbard. It is not, by any reasonable standard, a small claim. And it is not, as it turns out, unsupported.

What the episode actually argued

Perry and Hubbard spent three hours making a very specific case: that ibogaine, a plant alkaloid derived from the West African iboga shrub, currently classified as Schedule I in the United States, may be the most effective single-dose treatment ever observed for opioid dependence, alcoholism, methamphetamine addiction, and the constellation of post-traumatic stress disorder and traumatic brain injury that has defined the post-9/11 veteran cohort.

They are not the first people to say this. Howard Lotsof described ibogaine's anti-addictive properties in 1962. Researchers like Kenneth Alper and Deborah Mash have been running human studies for decades. What's different now is the political and scientific gravity behind the claim.

Texas committed $100 million in public funds to ibogaine research in 2025, the largest state-level psychedelic research initiative in American history. 181 of 188 state legislators signed on. Mississippi, Tennessee, and Kentucky are following. The Choctaw Nation is preparing to run clinical trials under tribal sovereignty. A former governor who once supported mandatory drug testing for welfare recipients is now the most visible advocate in the country for a psychoactive plant medicine. That is a political shift worth paying attention to.

The Stanford data is the spine of the whole argument

Every credibility question about ibogaine ends up at the same study: a thirty-veteran clinical trial run by Dr. Nolan Williams at Stanford Medicine, published in Nature Medicine. The participants were Special Forces veterans with documented repeated traumatic brain injuries. The protocol combined ibogaine with magnesium to mitigate the known cardiac risk. The results did not look like the results people expect from psychiatric interventions.

• → Average biological brain age reversed by 1.5 years. Some participants saw nearly five years of reversal.
• → 87% reported zero PTSD symptoms at six-month follow-up.
• → Significant reductions in depression, anxiety, and functional disability across every standardized instrument the researchers used.
• → Brain imaging showed rapid restoration of function in regions affected by repeated blast exposure.

That is not a marketing pitch. That is a peer-reviewed clinical result that no existing pharmaceutical treatment for PTSD or TBI has come close to producing. It is the single study you would cite if a skeptical relative asked you to defend any of what Perry said on the podcast.

Why Dr. Rael Cahn's research is the right academic lens

Dr. Rael Cahn, a clinical associate professor of psychiatry at the USC Keck School of Medicine, is not an ibogaine researcher. His lab at the USC Brain and Creativity Institute studies the neurophysiology of psilocybin, MDMA, and long-form meditation practice. His PhD thesis compared the EEG signatures of Vipassana meditators with the acute effects of psilocybin. He is the principal investigator on a study of the epigenetic regulation underlying the efficacy of MDMA-assisted psychotherapy for PTSD.

So why cite him in a piece about ibogaine?

Because Cahn's work describes the mechanism, the neurophysiological signature of psychedelic healing, that makes Perry's claims legible instead of miraculous. The pattern is the same across the class of compounds: disruption of the default mode network, a temporary collapse of the rigid self-referential loops that encode trauma and compulsion, a window of heightened neuroplasticity in which the nervous system can reorganize around a different set of emotional associations.

Dr. Gül Dölen's research at Johns Hopkins, referenced by Hubbard on the podcast, frames this as a re-opening of developmental "critical periods", windows in which the brain can relearn things it long ago decided were fixed. Cahn's neurophenomenology work gives you the subjective side of that same mechanism: ego dissolution, oceanic boundlessness, the experience of being temporarily unhooked from the identity the trauma was built around.

Ibogaine is unusual because it seems to do all of this inside a single thirty-six-hour session. It is the most compressed version of a mechanism that the broader psychedelic research field has been mapping for twenty years. Which is exactly why a study from a researcher who works on psilocybin and MDMA is the right reference point for a conversation about what ibogaine is doing. The class behaves like a class.

The Texas $100 million and the federal wall

The most important political argument in the episode was not about veterans. It was about federalism.

Ibogaine is Schedule I. That classification formally designates it as having no accepted medical use. The DEA has refused to include Schedule I substances in federal right-to-try legislation, which means terminally ill Americans who can legally try experimental chemotherapy drugs cannot legally try ibogaine. A presidential directive or act of Congress would be required to reschedule it.

Perry and Hubbard are running a parallel strategy. They are using state governments and tribal sovereignty to build the clinical evidence and the treatment infrastructure that will eventually force a federal reclassification. The Texas appropriation is the flagship. The Choctaw Nation's preparation to run trials under tribal law is the backstop. The Aspen summit that Hubbard referenced, with two hundred state officials from twenty-two states in attendance, is the recruiting operation.

This is not a fringe movement anymore. It is a coordinated, federalism-aware, evidence-based reform effort led by people with credentials and capital. That is the thing the episode actually announces, for anyone who wasn't already paying attention.

What the episode left out

The strongest argument we can make for taking ibogaine research seriously is that we are willing to name the parts of the story that are uncomfortable.

• → Cardiac risk is real. Ibogaine prolongs the QT interval and has been associated with deaths in unsupervised settings. The Stanford protocol's use of magnesium co-administration is one of the reasons the trial was defensible. Any program that does not take cardiac screening seriously is not a program, it is a liability.
• → It is not a one-shot panacea for everyone. The 80% resolution and 87% PTSD remission numbers are extraordinary, but they come from small trials with carefully screened participants. Integration, the weeks and months of therapeutic work after the dose, matters enormously.
• → The Mexico clinic gap is a serious problem. Quality varies enormously. Some clinics run medical-grade protocols with cardiologists on site. Others do not. Americans traveling for treatment are largely on their own to evaluate which is which.
• → Cost is a barrier. A supervised ibogaine session runs several thousand to several tens of thousands of dollars. The people who need it most are frequently the people least able to pay for it.

None of this invalidates the Perry and Hubbard thesis. All of it should be part of the conversation, and the fact that the podcast glossed over most of it is the one place where the episode's advocacy tone got ahead of its journalism.

Where this fits the bigger picture

Soul Syndicate covers psychedelic medicine as mental health infrastructure, not counterculture. That framing is load-bearing. The Rick Perry episode matters because it is the clearest mainstream signal yet that a specific class of compounds, ibogaine, psilocybin, MDMA, ketamine, is moving from the fringe into the standard-of-care conversation, driven by the same kind of evidence-based reform process that eventually got cannabis rescheduled.

If you want the psilocybin side of this story, our breakdown of the legal microdose loophole covers the consumer market that is already forming around the clinical research.